These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype. Katz JD; Ohnishi K; Lebow LT; Bonavida B J Exp Med; 1988 Nov; 168(5):1553-62. PubMed ID: 2460577 [TBL] [Abstract][Full Text] [Related]
23. Properties of reticulum cell sarcomas in SJL/J mice. VII. Nature of normal lymphoid cells proliferating in response to tumor cells. Lerman SP; Chapman-Alexander J; Umetsu D; Thorbecke GJ Cell Immunol; 1979 Mar; 43(1):209-13. PubMed ID: 380818 [No Abstract] [Full Text] [Related]
24. Mapping of SJL/J reticulum cell sarcoma tumor-associated Ia antigens by T cell hybridomas: characterization of tumor-specific and shared epitopes detected on IE+ allogeneic cells. Ohnishi K; Bonavida B J Immunol; 1986 Jul; 137(2):733-40. PubMed ID: 2424977 [TBL] [Abstract][Full Text] [Related]
25. Natural killer cell activity in reticulum-cell sarcomas of SJL/J mice. III. Characterization of the effector cells within RCS that mediate NK lysis. Fitzgerald KL; McMaster JS; Ponzio NM Int J Cancer; 1981 Nov; 28(5):635-45. PubMed ID: 7030971 [No Abstract] [Full Text] [Related]
26. Similarities between the syngeneic mixed lymphocyte response and lymphoma-induced T cell proliferation in SJL/J mice. Ponzio NM Behring Inst Mitt; 1983 May; (72):28-36. PubMed ID: 6085747 [TBL] [Abstract][Full Text] [Related]
27. Natural killer cell activity associated with reticulum cell neoplasms. Chang KS; Log T Int J Cancer; 1980 Mar; 25(3):405-16. PubMed ID: 6248470 [TBL] [Abstract][Full Text] [Related]
28. Refractoriness of lymph-node cells from tumour-bearing animals. Burk MW; Yu S; Ristow SS; McKhann CF Int J Cancer; 1975 Jan; 15(1):99-108. PubMed ID: 47843 [TBL] [Abstract][Full Text] [Related]
29. Interleukin-12-induced cytotoxicity against syngeneic B cell lymphomas of SJL/J mice. Wajchman J; Simmons WJ; Klein A; Koneru M; Ponzio NM Leuk Res; 2002 Jun; 26(6):577-90. PubMed ID: 12007506 [TBL] [Abstract][Full Text] [Related]
30. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation. Ohnishi K; Bonavida B J Immunol; 1987 Jun; 138(12):4524-9. PubMed ID: 2953807 [TBL] [Abstract][Full Text] [Related]
31. Non-H-2-linked control of in vivo growth of SJL/J-derived reticulum cell sarcoma in recombinant inbred strains between BALB/cKe and SJL/J mice. Sakano T; Wilbur SM; Bonavida B; Cohn M J Natl Cancer Inst; 1985 Oct; 75(4):669-73. PubMed ID: 3900512 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. Kirchner H; Muchmore AV; Chused TM; Holden HT; Herberman RB J Immunol; 1975 Jan; 114(1 Pt 1):206-10. PubMed ID: 122986 [TBL] [Abstract][Full Text] [Related]
33. Suppression of spontaneous reticulum cell sarcoma development and of syngeneic stimulator cell by anti-mu treatment of SJL/J mice. Katz IR; Asofsky R; Thorbecke GJ J Immunol; 1980 Sep; 125(3):1355-9. PubMed ID: 6774017 [TBL] [Abstract][Full Text] [Related]
34. Regulation of immune responses in SJL and F1 hybrid mice by gamma-irradiated syngeneic lymphoma cells. Katz IR; Nagase F; Bell MK; Ponzio NM; Thorbecke GJ J Natl Cancer Inst; 1984 Jan; 72(1):125-32. PubMed ID: 6198549 [TBL] [Abstract][Full Text] [Related]
39. Specific lymphocyte-target cell conjugate formation between tumor-specific helper T-cell hybridomas and IA-bearing RCS tumors and IE-bearing allogeneic cells. I. Role of Ia and both L3T4 and LFA-1 antigens in recognition/binding. Ohnishi K; Bonavida B J Immunol; 1986 Dec; 137(11):3681-8. PubMed ID: 2946766 [TBL] [Abstract][Full Text] [Related]
40. The in vivo depletion of V beta 17a+ T cells results in the inhibition of reticulum cell sarcoma growth in SJL/J mice. Evidence for the use of anticlonotypic antibody therapy in the control of malignancy. Katz JD; Lebow LT; Bonavida B J Immunol; 1989 Aug; 143(4):1387-95. PubMed ID: 2663994 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]